Novartis Offers $120 Million For Corthera Eyeing Phase III Acute Cardiology Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Relaxin enables the pharma to expand its reach in acute cardiology as its mega-drug Diovan faces patent expiries.